在过去5年的使用中，接受利伐沙班治疗的非瓣膜性心房颤动患者的临床特征发生变化了吗？
Has the clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban changed in the last 5 years of use?
作者信息
Pimentel Quezada Yesenia, Bonilla Palomas Juan Luis, Gámez López Antonio Luis, Moreno Conde Mirian, López Ibáñez María Cristina, Gallego de la Sacristana López-Serrano Ángel
机构信息
Área de Cardiología, Unidad de Gestión Clínica de Medicina Interna, Hospital San Juan de la Cruz, Úbeda (Jaén), Spain.
Unidad de Gestión Clínica de Medicina Interna, Hospital San Juan de la Cruz, Úbeda (Jaén), Spain.
出版信息
Future Cardiol. 2018 May;14(3s):47-53. doi: 10.2217/fca-2018-0026.
AIM
To analyze the evolution of clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban.
METHODS
Retrospective study in which patients treated with rivaroxaban were divided into two groups according to the data in which the initial prescription was performed (November 2012-December 2013 and January 2014-January 2017).
RESULTS
211 patients (mean age 76.7 ± 9.2 years; CHADS-VASc 3.8 ± 1.5; HAS-BLED 2.0 ± 0.8.) were included. Age and bleeding risk were higher in those subjects in which the prescription started earlier. Rates of stroke/TIA, major bleeding and intracranial hemorrhage were 2.3/4.2/0.6 events/100 patient-years, respectively.
CONCLUSION
Although, the initial prescription of rivaroxaban was mainly performed in very elderly patients and/or with a higher bleeding risk, this has been extended to the overall nonvalvular atrial fibrillation population.
目的
分析接受利伐沙班治疗的非瓣膜性心房颤动患者临床特征的演变。
方法
回顾性研究，根据初始处方时间（2012年11月至2013年12月和2014年1月至2017年1月）将接受利伐沙班治疗的患者分为两组。
结果
纳入211例患者（平均年龄76.7±9.2岁；CHADS-VASc评分3.8±1.5；HAS-BLED评分2.0±0.8）。处方开始较早的患者年龄和出血风险更高。卒中/短暂性脑缺血发作、大出血和颅内出血的发生率分别为2.3/4.2/0.6事件/100患者年。
结论
尽管利伐沙班的初始处方主要针对高龄患者和/或出血风险较高的患者，但现在已扩展至整个非瓣膜性心房颤动人群。
Zotero 插件